Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
Saved in:
Main Authors: | G. Biolcati (Author), S. Hanneken (Author), E. I. Minder (Author), N. J. Neumann (Author), J. H. P. Wilson (Author), P. J. Wolgen (Author), D. J. Wright (Author), A. J. Lloyd (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
by: G. Biolcatti, et al.
Published: (2021) -
Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
by: Jasmin Barman-Aksözen, et al.
Published: (2017) -
Acquired erythropoietic protoporphyria secondary to myelodysplastic syndrome: from mythology to oncologyAcquired Erythropoietic Protoporphyria Secondary to Myelodysplastic Syndrome: From Mythology to Oncology
by: Mirjana Urosevic-Maiwald, et al.
Published: (2024) -
Erythropoietic Protoporphyria in a Japanese Population
by: Megumi Mizawa, et al.
Published: (2019) -
Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria
by: Katelyn E. Madigan, et al.
Published: (2023)